At what age should routine prostate-specific antigen (PSA) screening be discontinued in men?

PSA Screening Discontinuation Age

Routine PSA screening should be discontinued at age 70 years for most men, with the critical exception that healthy men with minimal comorbidities may continue screening up to age 75 years if they have a life expectancy of at least 10-15 years.

Age-Based Recommendations

The most authoritative guidance comes from the 2018 USPSTF, which provides the clearest age cutoffs 1, 2:

• Age ≥70 years: Recommend against routine PSA screening (Grade D recommendation)
• Age 55-69 years: Shared decision-making approach (Grade C recommendation)

However, the 2018 NCCN guidelines offer a more nuanced approach that acknowledges individual health status 1:

• Age 45-75 years: Offer screening routinely
• Beyond age 75: Continue screening with caution only in healthy patients with little or no comorbidity

Life Expectancy as the Critical Factor

The decision to stop screening is fundamentally about life expectancy, not chronological age alone. Multiple guidelines converge on the principle that screening should cease when life expectancy falls below 10-15 years 1:

• American Urological Association: Recommend against screening in men with life expectancy <10-15 years
• European Association of Urology: Recommend against screening in men with life expectancy <15 years
• American College of Physicians: Recommend against screening in men with life expectancy <10 years

Risk-Stratified Discontinuation

Research supports a PSA-based approach to safely discontinue screening in elderly men 3, 4:

For men aged 75-80 years:

• PSA <3.0 ng/mL: Can safely discontinue screening—these men are unlikely to die from or develop aggressive prostate cancer during their remaining life 3
• PSA ≥3.0 ng/mL: Continue surveillance as risk of aggressive disease remains elevated

Race-specific thresholds for discontinuation at ages 75-80 4:

• African American men: PSA <6.0 ng/mL indicates low risk; safe to discontinue
• Caucasian men: PSA <3.0 ng/mL indicates low risk; safe to discontinue

Rationale for Age-Based Discontinuation

The harms of screening increase substantially after age 70 2:

• Higher false-positive rates
• Increased biopsy complications
• Greater treatment-related morbidity (urinary incontinence, erectile dysfunction, bowel symptoms)
• Competing mortality risks from other conditions
• Minimal mortality benefit given the slow-growing nature of most prostate cancers

The median age of death from prostate cancer is 80 years, and many elderly men with prostate cancer never experience symptoms 2. The 10-year prostate cancer mortality rate for well- or moderately differentiated tumors in men aged 66-69 is only 0-7%, while other-cause mortality is 0-22% 5.

Common Pitfalls to Avoid

1. Screening men with limited life expectancy: Approximately 33% of elderly US men with competing medical comorbidities at high risk of dying from other causes still undergo inappropriate screening 1

2. Failing to have shared decision-making discussions: Two-thirds of men report no past discussion with physicians about screening advantages, disadvantages, or scientific uncertainty 1

3. Ignoring baseline PSA values: A single PSA measurement at age 75-80 can guide discontinuation decisions more precisely than age alone 3, 4

4. Continuing screening in men >70 without considering health status: The blanket age 70 cutoff applies to average-risk men; exceptionally healthy men may benefit from continued screening to age 75 1

Practical Algorithm

For men approaching age 70:

1. Assess overall health status and comorbidities
2. Estimate life expectancy (use validated calculators)
3. Check current PSA level
4. Apply decision rules:
   • Life expectancy <10 years → Stop screening
   • Age ≥70 with average health → Stop screening
   • Age 70-75, excellent health, life expectancy >10-15 years, PSA ≥3.0 ng/mL → Consider continuing with informed discussion
   • Age ≥75 → Stop screening (rare exceptions for exceptionally healthy men)